Compare AU & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AU | ROIV |
|---|---|---|
| Founded | 1944 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.5B | 26.1B |
| IPO Year | 2023 | 2021 |
| Metric | AU | ROIV |
|---|---|---|
| Price | $115.67 | $35.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 9 |
| Target Price | ★ $119.00 | $28.94 |
| AVG Volume (30 Days) | 2.8M | ★ 5.6M |
| Earning Date | 05-08-2026 | 05-28-2026 |
| Dividend Yield | ★ 3.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $8,260,000.00 |
| Revenue This Year | $38.71 | N/A |
| Revenue Next Year | $2.89 | $744.61 |
| P/E Ratio | $23.93 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $56.62 | $11.97 |
| 52 Week High | $129.14 | $37.97 |
| Indicator | AU | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 71.99 | 56.64 |
| Support Level | $76.14 | $33.56 |
| Resistance Level | $129.14 | $37.49 |
| Average True Range (ATR) | 3.40 | 1.05 |
| MACD | 1.60 | -0.01 |
| Stochastic Oscillator | 83.96 | 63.93 |
Anglogold Ashanti PLC is an independent gold mining company. It has a diversified asset portfolio, including production from operations in eight countries (Argentina, Australia, Brazil, Egypt, Ghana, Guinea, the DRC, and Tanzania), supported by greenfield projects in the United States and Colombia. The company's main product is gold, which once mined, is processed into dore (unrefined gold bars) on site and then dispatched to precious metals refineries. Geographically, Anglogold generates maximum revenue from its operations in Africa (comprising operations at Kibali, Iduapriem, Obuasi, Siguiri, Geita, and Sukari mines), followed by Australia (including Sunrise Dam and Tropicana), and the Americas (comprising Cerro Vanguardia, AngloGold Ashanti Mineracao, and Serra Grande operations).
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.